

Singapore

24 October 2025

Singapore's industrial production surprised with red-hot growth momentum in September!

Selena Ling
Head of Research and Strategy
lingssselena@ocbc.com

- Singapore's manufacturing output surged to 16.1% YoY, up from -9.0% in August surpassing consensus forecast of 0.5% and our forecast of 2.5% YoY.
- This brought 3Q25 manufacturing growth from the 0% YoY (initially estimated in the advance 3Q25 GDP growth estimates) to 5% YoY, which also implies that 3Q25 GDP growth could also see a significant upgrade from 2.9% YoY to 4% YoY.
- Even assuming that 4Q25 growth momentum tapers as US reciprocal tariffs start to weigh, full-year GDP growth may overshoot the 3% YoY handle to come in around 3.3% YoY.

Huge upside surprise as Singapore's manufacturing output surged 16.1% YoY (26.3% MoM sa) in September, beating the Bloomberg consensus forecast of 0.5% YoY (8.7% MoM sa) as well as our forecast of 2.5% YoY (10.3% MoM sa). This was also a big turnaround from the disappointing August data which was revised to -9.0% YoY (-11.0% MoM sa) from initial estimates of -7.8% YoY (-9.7% MoM sa). Given the wild swings in the August and September IP data, it may make sense to average the two months performance to 3.7% YoY, which is still lower than the same period last year (15.5% YoY). This brought 3Q25 manufacturing growth from the 0% YoY (initially estimated in the advance 3Q25 GDP growth estimates) to 5% YoY, which also implies that **3Q25 GDP growth could also see a significant upgrade from 2.9% YoY to 4% YoY**. If this materialises, this would also elevate the 1Q-3Q25 GDP growth from 3.9% to 4.2% YoY. **Even assuming that 4Q25 growth momentum tapers as US reciprocal tariffs start to weigh, full-year GDP growth may overshoot the 3% YoY handle to come in around 3.3% YoY.**

The September manufacturing upside was largely thanks to a big snapback in pharmaceuticals and also double-digit YoY growth in electronics and transport engineering. Excluding biomedical, IP is more muted at 5.4% YoY (0.8% MoM sa). Hard to tell how much of this surprise surge is due to front loading ahead of potential pharmaceutical tariffs and/or due to new mix of ingredients production lines. Global pharmaceutical companies are likely trying to strike some deals with the U.S. to lower their tariffs if they commit to investments and/or on shoring of production in the U.S. In addition, it is possible that sectoral tariffs, whether on pharmaceutical or semiconductors, may not be as punitive as what the headlines may suggest.


Outside of the biomedical sector, other clusters that performed in September were electronics (13.2% YoY due to infocomms & consumer electronics, other electronics modules & components and semiconductors), transport engineering (13.8% YoY aided by aerospace due to ongoing activity in aircraft parts and maintenance, repair and overhaul jobs from commercial airlines). On the contrary, precision engineering cluster contracted for the second consecutive month by 5.9% YoY in September, weighed down by machinery & systems (namely reduced production of front-end

Follow our podcasts by searching 'OCBC Research Insights' on Telegram!

semiconductor equipment), whilst general manufacturing industries also shrunk for the 9th straight month by 4.7% YoY mainly dragged down by food, beverages & tobacco (namely lower output of beverage and coca products).

The irony is that despite US tariffs, Singapore's manufacturing sector may actually outperform in 2025 vis-a-vis 2024! Jan-Sep25 manufacturing growth is already 5.0% YoY, compared to 3.2% for same period last year, and that is without accounting for the low base in 4Q24. It's possible we will get some payback in terms of a moderation in manufacturing in coming months when sectoral tariffs, such as on pharmaceutical or semiconductor, materialise, but increasingly global affected firms are also adjusting to recalibrate their supply chains and potentially leveraging on Singapore's relatively lower tariffs imposed by the U.S. and as they negotiate with the U.S. on lowering tariffs by pledging to onshore some production/investments to the U.S.

Industrial Production



Source: EDB, CEIC, OCBC.

Macro Research

Selena Ling
Head of Research & Strategy
lingssselena@ocbc.com

Tommy Xie Dongming
Head of Asia Macro Research
xied@ocbc.com

Keung Ching (Cindy)
Hong Kong & Macau Economist
cindyckeung@ocbc.com

Herbert Wong
Hong Kong & Taiwan Economist
herberhtwong@ocbc.com

Lavanya Venkateswaran
Senior ASEAN Economist
lavanyavenkateswaran@ocbc.com

Ahmad A Enver
ASEAN Economist
ahmad.enver@ocbc.com

Jonathan Ng
ASEAN Economist
jonathannq4@ocbc.com

Ong Shu Yi
ESG Analyst
shuyionq1@ocbc.com

FX/Rates Strategy

Frances Cheung, CFA
Head of FX & Rates Strategy
francescheung@ocbc.com

Christopher Wong
FX Strategist
christopherwong@ocbc.com

Credit Research

Andrew Wong
Head of Credit Research
wongvkam@ocbc.com

Ezien Hoo, CFA
Credit Research Analyst
ezienhoo@ocbc.com

Wong Hong Wei, CFA
Credit Research Analyst
wonghongwei@ocbc.com

Chin Meng Tee, CFA
Credit Research Analyst
mengteechin@ocbc.com

This report is solely for information purposes and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein or to participate in any particular trading or investment strategy. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this report is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this report may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This report may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether the investment product mentioned herein is suitable for you. Oversea-Chinese Banking Corporation Limited ("OCBC Bank"), Bank of Singapore Limited ("BOS"), OCBC Investment Research Private Limited ("OIR"), OCBC Securities Private Limited ("OSPL") and their respective related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future, interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial or securities related services to such issuers as well as other parties generally. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, BOS, OIR, OSPL or other members of the OCBC Group and any of the persons or entities mentioned in this report of which OCBC Bank and its analyst(s) are not aware due to OCBC Bank's Chinese Wall arrangement. This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

The information provided herein may contain projections or other forward looking statements regarding future events or future performance of countries, assets, markets or companies. Actual events or results may differ materially. Past performance figures are not necessarily indicative of future or likely performance.

Privileged / confidential information may be contained in this report. If you are not the addressee indicated in the message enclosing the report (or responsible for delivery of the message to such person), you may not copy or deliver the message and/or report to anyone. Opinions, conclusions and other information in this document that do not relate to the official business of OCBC Bank, BOS, OIR, OSPL and their respective connected and associated corporations shall be understood as neither given nor endorsed.

Co.Reg.no.: 193200032W

Follow our podcasts by searching 'OCBC Research Insights' on Telegram!